Chinook Therapeutics, Inc. (KDNY) Research

Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.

Market snapshot

Symbol
KDNY
Price
$40.39
Day change
+0.22%
Market cap
$2.7B
P/E ratio
-14.08x
52-week range
18.34-40.51
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$30.00

Peer companies

  • BELLUS Health Inc. (BLU)
  • Calliditas Therapeutics AB (publ) (CALT)
  • DICE Therapeutics, Inc. (DICE)
  • Fusion Pharmaceuticals Inc. (FUSN)
  • Longboard Pharmaceuticals, Inc. (LBPH)
  • MorphoSys AG (MOR)
  • Morphic Holding, Inc. (MORF)
  • Myovant Sciences Ltd. (MYOV)

Recent insider activity

  • Thomas Dolca — D-Return (13300 shares) on 2023-08-11
  • Thomas Dolca — D-Return (23522 shares) on 2023-08-11
  • Thomas Dolca — D-Return (5948 shares) on 2023-08-11
  • Thomas Dolca — D-Return (13300 shares) on 2023-08-11
  • Oxtoby Andrew — D-Return (160000 shares) on 2023-08-11

Open Chinook Therapeutics, Inc. (KDNY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.